latest news releases from the newsroom
Amersham plc appoints David Challen to the Board of Directors
BUCKINGHAMSHIRE, U.K., Aug. 5, 2003 (PRIMEZONE) -- Amersham plc (LSE:AHM) (NYSE:AHM) (OSE:AHM) today announces the appointment to the Board of Directors of Mr. David Challen as a Non-Executive Director, with immediate effect. David Challen, 60, is currently vice-chairman, European Investment Bank at Citigroup, and previously served as Co-Chairman at Schroder Salomon Smith Barney following the merger of Schroder's Investment Banking business where David had served in many senior positions over a 28-year period before being elected Chairman in 1997.
ASM International NV
ASM Receives ISO 14001 Certification
BILTHOVEN, The Netherlands, Aug. 5, 2003 (PRIMEZONE) -- ASM International N.V. (Nasdaq:ASMI) (Euronext Amsterdam:ASM) announced today that it's subsidiaries ASM Europe B.V. and ASM Japan K.K. have acquired ISO 14001 certification. The company's other manufacturing facility in Phoenix, USA is targeted for certification later in 2003.
Integra LifeSciences Holdings Corp.
Integra NeuroSciences Reports Positive Clinical Results from a Five-Year Study of the OSVII Smart Valve for the Treatment of Hydrocephalus
PLAINSBORO, N.J., August 5, 2003 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the results of a five-year prospective, multicenter study of the OSVII(R) Smart Valve(TM), a flow-regulating shunt used for the treatment of hydrocephalus. The study was conducted by Dr. Patrick W. Hanlo of The Department of Neurosurgery, Ultrecht University Medical Center, and Center for Biostatistics, Ultrecht University, Ultrecht, The Netherlands, et al. The results of the study, which were published in the July 2003 edition of the Journal of Neurosurgery , reveal an exceptionally low rate of valve related complications with fewer incidents of mechanical dysfunction than other valves previously studied. The investigators in this study found that the OSV II Smart Valve survival rate was 62% at five years, whereas previous independent studies have shown a 60% survival rate at one year with other valves tested.